• Own end-to-end MIDD evidence strategies for a therapeutic or sub-therapeutic area, guiding data prioritisation, integration, quality assessment, and application of advanced modelling to drive scientific, program, and business decisions • Act as the MIDD technical authority, leading M&S plans, analyses, and reports, coaching internal and external analysts, and supporting regulatory interactions involving quantitative evidence • Lead the delivery of robust, transparent MIDD evidence to de-risk and accelerate programs, advising on optimized internal and regulatory MIDD strategies • Drive consistent use of established M&S methodologies (e.g., MBMA, disease progression modelling) and integrate emerging technologies (AI/ML, SciML) through standards, training, and best practices • Build strong internal and external networks across CPMS, QSP, AI/ML, digital, biomarkers, and academia to shape future methodologies and strengthen GSK’s scientific and regulatory presence